Neurocrine Biosciences has reported positive results from pooled analyses of the long-term effects of Ingrezza (valbenazine) in decreasing abnormal movements in tardive dyskinesia (TD) disorder.

TD is characterised by persistent involuntary movements of the face, torso and/or other body parts.

Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor intended to minimise the amount of dopamine in a brain region that regulates movement and motor function.

It has US Food and Drug Administration (FDA) approval to treat adults suffering from TD.

Pooled analyses from the Phase III KINECT 3 and KINECT 4 trials showed that a once-daily 40mg dose of the drug led to a response on the Abnormal Involuntary Movement Scale (AIMS) scale in 53.7% of patients treated for 48 weeks.

Ingrezza also demonstrated a Clinical Global Impression of Change-Tardive Dyskinesia (CGI-TD) response in 65.5% of patients.

In addition, data from the Phase III KINECT 3 trial revealed early response following two weeks of therapy with a 40mg or 80mg dose in 50% of participants.

Irrespective of the response at two weeks, meaningful reductions in the disorder were observed with long-term treatment.

According to the data, the drug was generally well-tolerated without any new safety concerns or notable worsening of psychiatric symptoms.

Neurocrine Biosciences chief medical officer Eiry Roberts said: “The analyses of pooled data continue to support the growing body of evidence that Ingrezza is an effective treatment for the long-term management of tardive dyskinesia.

“It is important to choose the best dosing option of Ingrezza and continue treatment to achieve long-term outcomes as tardive dyskinesia varies from patient to patient as well as their treatment response.”

The Phase III KINECT 3 and KINECT 4 studies were conducted in 234 and 163 moderate to severe TD patients, respectively.